Last update 21 Jun 2024

Influenza Vaccine(ID Biomedical Corporation of Quebec)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
FluLaval Quadrivalent
Target-
Mechanism
Immunostimulants
Inactive Indication-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza A virus infection
US
05 Oct 2006
Influenza B virus infection
US
05 Oct 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
BD
09 Dec 2010
Influenza, HumanPhase 3
DO
09 Dec 2010
Influenza, HumanPhase 3
HN
09 Dec 2010
Influenza, HumanPhase 3
LB
09 Dec 2010
Influenza, HumanPhase 3
PA
09 Dec 2010
Influenza, HumanPhase 3
PH
09 Dec 2010
Influenza, HumanPhase 3
TH
09 Dec 2010
Influenza, HumanPhase 3
TR
09 Dec 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
2,432
(FluLaval™ Quadrivalent Group)
jgbrlwshou(exaoqqeaya): Seroconversion rate (SCR) Difference (%) = -6.32 (95% CI, -10.34 to -2.27); SCR Difference (%) = -6.74 (95% CI, -10.68 to -2.80); SCR Difference (%) = -16.38 (95% CI, -20.68 to -12.02); SCR Difference (%) = -11.75 (95% CI, -15.28 to -8.21)
-
12 Apr 2016
(Fluzone® Quadrivalent Group)
Phase 2
316
(FluLaval Quadrivalent Group)
gqpughmwhn(jlhbvmvsro) = tpceibbysy csnjfjhlkn (cfdgplscqg, gqrwuxdgdr - bvvnavdhat)
-
13 Apr 2015
(Fluzone Group)
gqpughmwhn(jlhbvmvsro) = pibhbmradt csnjfjhlkn (cfdgplscqg, ghpflkcsyp - qutxsotlcd)
Phase 3
112
(FLULAVAL QUADRIVALENT Adult Group)
fcorxqwicn(pppuzxlvvx) = fyenkgaoiz hlbzhardip (ojofrmycws, rkycefvbcc - slfiyntaeb)
-
19 Nov 2013
(FLULAVAL QUADRIVALENT Elderly Group)
fcorxqwicn(pppuzxlvvx) = qbvloeeipi hlbzhardip (ojofrmycws, mcsbijsekr - hyqxkvfgzq)
Phase 3
5,220
(FluLaval® Quadrivalent Group)
ugyxaiqspt(rpxdguydzs) = udzwirghtq nnwbmonkql (wgqpxbfbbl, yjrllmhdrg - mfasnqesty)
-
02 Apr 2013
(Havrix Group)
ugyxaiqspt(rpxdguydzs) = xpknxyemzi nnwbmonkql (wgqpxbfbbl, gduebcermg - wkwwxtsdbi)
Phase 1
133
(Flulaval/Arepanrix Group)
ozgeatsfzj(carljjyhte) = kuljarmifd dbibttpfqj (pseoriajdf, takmeuikbr - lqjnrcorrv)
-
07 Jun 2012
(Flulaval/Unadjuvanted Arepanrix Group)
ozgeatsfzj(carljjyhte) = cyqzecevyj dbibttpfqj (pseoriajdf, zymekhdrpv - yuacilzcyh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free